# Recent Cannabis Research Digest 2026 – March 19 Update > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/recent-cannabis-research-digest-2026-march-19/ > **Published:** 2026-03-19T22:01:04-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:04:57-04:00 > **Clinical Summary:** Explore the recent cannabis research digest 2026 featuring 20 peer-reviewed studies on clinical relevance and evidence quality from March 19, 2026. --- CED Clinical Relevance #85 Research Authority Peer-reviewed research curated for clinical relevance and evidence quality. Recent research digest. 20 of 20 most recent studies from our monitored feeds. CED Clinical Relevance #81 Research Authority Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial. *Schuster Nathaniel M et al.* Headache • 2026 # Clinical Summary This randomized controlled trial tested vaporized cannabis products containing different ratios of THC and CBD against placebo for treating acute migraine attacks. The study represents the first rigorous clinical trial to evaluate whether cannabinoids can effectively reduce migraine symptoms compared to placebo. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41469488/) | [PMC PDF](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197380/) | [DOI](https://doi.org/10.3389/fneur.2022.871187) CED Clinical Relevance #82 Research Authority Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support. *Cazares Christian et al.* Translational psychiatry • 2026 # Clinical Summary This study examined how purified cannabidiol (CBD) treatment affects brain activity and [cognitive function](https://cedclinic.com/reverse-cholesterol-transport-function-cannabis-users/) in boys with autism who need significant support, finding that CBD blood levels correlated with changes in brain wave patterns and improvements in visual-motor coordination and non-verbal reasoning abilities. The research suggests that measuring CBD metabolite levels in the blood may help predict which boys with autism will benefit most from CBD treatment based on their brain electrical activity patterns. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41611664/) | [PMC PDF](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169229/) | [DOI](https://doi.org/10.1038/s41398-026-03815-y) CED Clinical Relevance #83 Research Authority Effects of cannabidiol in alcohol use disorder patients with and without co-occurring post-traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof-of-concept trials. *Bogenschutz Michael P et al.* Alcohol, clinical & experimental research • 2026 # Clinical Summary Two randomized trials tested cannabidiol (a cannabis component) for treating alcohol use disorder alone and combined with PTSD, finding that the drug was well-tolerated but did not improve drinking outcomes or PTSD symptoms compared to placebo. These results indicate cannabidiol is safe to use in these patient populations but lacks evidence of therapeutic benefit for reducing alcohol use or trauma-related symptoms. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41312717/) | [PMC PDF](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092268/) | [DOI](https://doi.org/10.1111/acer.70212) CED Clinical Relevance #84 Research Authority Cannabis use measurement: Identifying the optimal metric for broad research applications. *Skrzynski Carillon J et al.* Addiction (Abingdon, England) • 2026 # Clinical Summary This study compared different methods of measuring cannabis use to determine which best reflects actual cannabis exposure in the body by checking blood cannabinoid levels. The research found that certain cannabis use metrics more accurately predicted blood cannabinoid levels than others, with differences potentially varying based on sex and age. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41070711/) | [PMC PDF](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436564/) CED Clinical Relevance #85 Research Authority Sleep apnea and substance use: a meta-analysis. *Mauries Sibylle et al.* Sleep medicine reviews • 2026 # Clinical Summary This meta-analysis of 28 studies found that substance users, particularly those using alcohol, tobacco, cannabis, opioids, and cocaine, have significantly higher apnea-hypopnea index scores compared to non-users, indicating more severe sleep apnea. The results suggest that commonly abused substances worsen obstructive sleep apnea severity, highlighting the importance of screening for and treating sleep apnea in patients with substance use disorders. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41564681/) | [DOI](https://doi.org/10.1016/j.smrv.2025.102228) CED Clinical Relevance #86 Research Authority Driving after cannabis consumption among US adults ages 50 years and older: A short communication. *Bonar Erin E et al.* Drug and alcohol dependence • 2026 # Clinical Summary Among U.S. adults age 50 and older who use cannabis, a significant proportion report driving after cannabis consumption, which represents a public health concern regarding impaired driving risk in this age group. The study examined prevalence rates and identifying characteristics of older adults who drive after cannabis use to inform prevention strategies tailored to aging populations. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41330071/) | [DOI](https://doi.org/10.1016/j.drugalcdep.2025.112985) CED Clinical Relevance #87 Research Authority The Prevalence of Cannabis Use Disorder in Individuals with Anxiety or Related Disorders: A Systematic Review. *Coles Ashlee R L et al.* Journal of dual diagnosis • 2026 Among people with anxiety or related disorders, the rate of concurrent cannabis use disorder ranges from about 3% to 20% based on studies of general population samples. This substantial overlap suggests that cannabis use disorder and [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) frequently occur together and may warrant coordinated clinical assessment and treatment approaches. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41447562/) | [DOI](https://doi.org/10.1080/15504263.2025.2606019) CED Clinical Relevance #88 Research Authority Neurodevelopmental, Pharmacological and Substance Use Factors in the Association Between ADHD and First-Episode Non-Affective Psychosis: A Systematic Review. *Ricci Valerio et al.* Early intervention in psychiatry • 2026 # Clinical Summary Individuals with ADHD have an increased risk of developing first-episode psychosis, with this association influenced by brain development differences, medication effects, and substance use patterns. The review suggests that careful assessment of ADHD symptoms, monitoring of psychiatric medication side effects, and prevention of substance abuse are important clinical considerations in managing patients at risk for psychotic disorders. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41496432/) | [DOI](https://doi.org/10.1111/eip.70123) CED Clinical Relevance #89 Research Authority Latent profiles of maternal psychopathology and risk for lifetime/perinatal substance use: Findings from the HBCD study. *Valdes Viviane et al.* Journal of affective disorders • 2026 # Clinical Summary This study identified distinct profiles of maternal mental health conditions during pregnancy by analyzing patterns of multiple psychological disorders and substance use together, rather than examining single diagnoses in isolation. The researchers found that socioeconomic factors influenced which mental health symptoms mothers experienced, and different psychological profiles were associated with varying patterns of substance exposure during pregnancy and throughout mothers’ lifetimes. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41455530/) | [DOI](https://doi.org/10.1016/j.jad.2025.121043) CED Clinical Relevance #80 Research Authority Fear of recurrence, secondary cancers, and health problems in long-term survivors of childhood cancer: Findings from a Canadian cohort. *Tutelman Perri R et al.* Cancer • 2026 # Clinical Summary Childhood cancer survivors experience significant fears about disease recurrence, secondary cancers, and future health problems years after completing treatment. These fears are associated with physical functioning limitations and psychosocial symptoms, indicating that long-term psychological support addressing these concerns is an important part of survivorship care. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41644475/) | [PMC PDF](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1466633/) | [DOI](https://doi.org/10.1370/afm.26) CED Clinical Relevance #81 Research Authority Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study. *Kang Jiseung et al.* Nature medicine • 2026 # Clinical Summary Drug use disorders affecting amphetamines, cannabis, cocaine, and opioids have increased globally from 1990 to 2023, with disability-adjusted life-years rising from 169.3 to 212.0 per 100,000 people. This study demonstrates that substance use disorders represent a growing public health burden across 204 countries and territories worldwide. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41545593/) | [PMC PDF](https://www.ncbi.nlm.nih.gov/pmc/articles/2831344/) CED Clinical Relevance #82 Research Authority Therapeutic Use of Cannabis and Cannabinoids: A Review. *Hsu Michael et al.* JAMA • 2026 # Clinical Summary Cannabis and cannabinoid products are increasingly used for medical purposes, with FDA-approved applications for treating HIV/AIDS-related appetite loss, chemotherapy-induced nausea and vomiting, and certain childhood seizure disorders. Research indicates a small but measurable benefit of cannabinoids for these conditions, while CBD in particular has gained popularity for therapeutic use despite lacking psychoactive effects. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41296368/) | [DOI](https://doi.org/10.1001/jama.2025.19433) CED Clinical Relevance #83 Research Authority Short-term effects of cannabis legalisation in Germany on driving under the influence of cannabis: a difference-in-differences analysis using Austria as a control. *Schranz Anna et al.* The Lancet regional health. Europe • 2026 # Clinical Summary This study compared cannabis use and driving under the influence patterns in Germany before and after legalisation in April 2024, using Austria as a control group to isolate the effects of the policy change. The research examined whether legalisation led to increased cannabis use, driving under the influence of cannabis, and combined use with alcohol or other drugs in the eight months following implementation. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41631167/) | [PMC PDF](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676961/) | [DOI](https://doi.org/10.2785/706535) CED Clinical Relevance #84 Research Authority Modulating the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies. *Costa Gabriel P A et al.* Molecular psychiatry • 2026 # Clinical Summary This systematic review found that modulating the endocannabinoid system, particularly through CB-1 receptor antagonists, shows promise as a potential treatment approach for alcohol use disorder based on evidence from both animal and human studies. The endocannabinoid system’s involvement in reward, stress, and mood regulation makes it an attractive therapeutic target for managing this chronic condition that currently has limited medication options available. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41760917/) | [PMC PDF](https://www.ncbi.nlm.nih.gov/pmc/articles/5240584/) CED Clinical Relevance #85 Research Authority Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review. *Sherman Justin J et al.* Cannabis and [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) • 2026 # Summary This systematic review examined whether medical cannabis and cannabinoid-based medicines could reduce pain in adults with diabetes-related nerve damage, comparing treated patients to those receiving placebo or standard care. The review searched major medical databases for randomized controlled trials to evaluate both the pain-relief effectiveness and safety of these cannabis treatments as an add-on therapy for diabetic peripheral neuropathy. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41714301/) | [DOI](https://doi.org/10.1177/25785125261425444) CED Clinical Relevance #86 Research Authority Reasons for cannabis use among adults with disabilities: Findings from the 2023-2024 National Survey on Health and Disabilities. *Schulz Jonathan A et al.* Disability and health journal • 2026 # Clinical Summary Adults with disabilities report significantly higher cannabis use rates than the general population, with pain management and symptom relief being primary motivations for their use. This study provides important insights into the specific reasons why disabled individuals use cannabis, highlighting the need for healthcare providers to understand cannabis use patterns in this vulnerable population. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41238503/) | [DOI](https://doi.org/10.1016/j.dhjo.2025.101979) CED Clinical Relevance #87 Research Authority Identifying vulnerable groups in academic burnout among higher education students: lifestyle and sociodemographic characteristic. *Holm Marja Eliisa et al.* BMC public health • 2026 # Clinical Summary This study of Finnish higher education students identified distinct lifestyle groups through statistical analysis and found that students with poorer lifestyle habits (low physical activity, substance use, poor diet, and insufficient sleep) experienced significantly higher rates of academic burnout. Certain sociodemographic groups, including those with lower socioeconomic status and specific age ranges, were particularly vulnerable to burnout when combined with unhealthy lifestyle patterns. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41639679/) | [PMC PDF](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484130/) | [DOI](https://doi.org/10.1007/s41252-022-00307-0) CED Clinical Relevance #88 Research Authority Common and distinct neurofunctional signatures of dynamic naturalistic emotion regulation strategies. *Jiang Heng et al.* Nature communications • 2026 # Clinical Summary This study used brain imaging during naturalistic scenarios to identify both shared and distinct neural patterns supporting two effective emotion regulation strategies: reappraisal (reinterpreting emotions) and acceptance (allowing emotions without judgment). The findings suggest that while these strategies activate some overlapping brain regions involved in emotion control, they also engage distinct neural processes that reflect their fundamentally different cognitive approaches to managing negative feelings. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41844656/) | [DOI](https://doi.org/10.1038/s41467-026-70708-5) CED Clinical Relevance #89 Research Authority First-episode psychosis and substance use involvement across birth cohorts in Canada: a retrospective longitudinal population-based study. *Myran Daniel T et al.* The lancet. Psychiatry • 2026 # Clinical Summary This study found that rates of first-episode psychosis in Ontario, Canada have changed across recent birth cohorts from 2006 to 2023, with substance use involvement increasingly present in these psychotic episodes. The research demonstrates a concerning link between rising substance use in North America and the development of psychotic disorders in adolescents and young adults. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41720572/) | [DOI](https://doi.org/10.1016/S2215-0366(25)00395-5) CED Clinical Relevance #80 Research Authority Psychotic or Not, Mania Hurts: A 5-Year Cohort Study With a Spotlight on the Non-Psychotic Subtype and Mixed Features. *Andreu Helena et al.* Acta psychiatrica Scandinavica • 2026 # Clinical Summary This 5-year study found that non-psychotic mania causes significant clinical harm and functional impairment comparable to psychotic mania, challenging the traditional view that psychotic symptoms alone define severity in bipolar disorder. Patients hospitalized for non-psychotic manic episodes experienced similar rates of relapse, hospitalization, and poor outcomes as those with psychotic features, indicating that the absence of psychosis does not predict better prognosis. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41320178/) | [DOI](https://doi.org/10.1111/acps.70049) Digest generated March 19, 2026 at 10:00 PM [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Research Digest: 5 Recent Studies – March 25, 2026](https://cedclinic.com/real-time-long-term-effects-medical-marijuana-research/) A concise summary of 5 recent cannabis-related studies published shortly after the March 19 digest. [Read More](https://cedclinic.com/real-time-long-term-effects-medical-marijuana-research/) [Research Digest: 20 Recent Studies – May 02, 2026](https://cedclinic.com/cannabinoid-based-interventions-autism-safety-effectiveness-2026/) An updated digest featuring 20 recent [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) studies from May 2026. [Explore Studies](https://cedclinic.com/cannabinoid-based-interventions-autism-safety-effectiveness-2026/) [Research Digest: 40 Recent Studies – March 20, 2026](https://cedclinic.com/research-digest-cannabis-clinical-studies-march-2026/) A comprehensive digest covering 40 recent cannabis research studies published the day after the March 19 digest. [View Digest](https://cedclinic.com/research-digest-cannabis-clinical-studies-march-2026/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Research%20Digest%3A%2020%20Recent%20Cannabis%20Studies%20-%20March%2019%2C%202026&url=https%3A%2F%2Fcedclinic.com%2Frecent-cannabis-research-digest-2026-march-19%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Frecent-cannabis-research-digest-2026-march-19%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Research%20Digest%3A%2020%20Recent%20Cannabis%20Studies%20-%20March%2019%2C%202026%20https%3A%2F%2Fcedclinic.com%2Frecent-cannabis-research-digest-2026-march-19%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).